# Patent Watch: Kare Claims New Cannabinoid Derivati

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/patent-watch-patent-watch-kare-claims-new-cannabinoid-deri-2026-10-06/
> **Published:** 2026-10-06T11:43:39-04:00 | **Last Modified / Clinically Audited:** 2026-10-06T11:52:00-04:00
> **Clinical Summary:** The application claims cannabinoid derivatives, related chemical precursors, and potential uses, with classifications suggesting modified cannabinoid ring

---

PATENT WATCH
 US20260209198A1
 
 

# Patent Watch: Kare Claims New Cannabinoid Derivatives and Precursors

 
 **Assignee:** KARE CHEMICAL TECHNOLOGIES INC.
 **Inventors:** Kamaluddin ABDUR-RASHID, Wenli JIA, Kareem ABDUR-RASHID
 **Published:** 2026-07-23
 
 

 
 Invention Summary & Claims
 

The application claims cannabinoid derivatives, related chemical precursors, and potential uses, with classifications suggesting modified cannabinoid ring structures and organosilicon-containing intermediates. These compounds may function as potential active pharmaceutical ingredients or as intermediates for manufacturing cannabinoids, rather than as excipients or a distinct delivery system.

 

 

## Clinical Perspective & Therapeutic Significance

 

Chemical modification could eventually improve properties such as stability, receptor selectivity, solubility, metabolism, or manufacturing consistency. However, the patent filing does not establish superior bioavailability, safety, dosing, or therapeutic efficacy in patients, and each derivative would require pharmacologic and clinical validation.

 

## Intellectual Property & Market Landscape

 

Kare Chemical Technologies appears positioned around proprietary cannabinoid synthesis and medicinal chemistry rather than conventional plant extracts, edibles, or vape products. If the claimed structures or precursor pathways prove scalable, the IP could support licensing, pharmaceutical development, or more efficient production of differentiated cannabinoid candidates.

 
 **Official Source Document:** Review the primary patent disclosure and full claims on [Google Patents (US20260209198A1)](https://patents.google.com/patent/US20260209198A1/en).
 

 
 Editorial Commentary
 

This is a potentially meaningful chemistry platform, but its patient relevance depends on whether the claimed molecules demonstrate measurable advantages over established cannabinoids. Patent protection alone should not be interpreted as evidence of clinical benefit.

 

 
 

### Frequently Asked Questions

 
 Could these cannabinoid derivatives work better than THC or CBD?
 Possibly, but chemical novelty does not guarantee improved efficacy or safety. Comparative laboratory studies, pharmacokinetic testing, and controlled human trials would be needed.

 Does publication of this patent mean the compounds have completed clinical trials?
 No. A published patent application establishes claimed intellectual property and does not demonstrate regulatory approval, completed trials, or proven therapeutic efficacy.

 When might products based on this patent become available?
 No reliable timeline can be established from the application alone. Availability would depend on compound selection, manufacturing, preclinical toxicology, clinical trials, regulatory review, and commercialization decisions.

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).